These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23329850)

  • 21. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
    Durbin AP; Kirkpatrick BD; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Opert K; Jarvis AP; Sabundayo BP; McElvany BD; Sendra EA; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2016 Sep; 214(6):832-5. PubMed ID: 26908742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
    Kirkpatrick BD; Whitehead SS; Pierce KK; Tibery CM; Grier PL; Hynes NA; Larsson CJ; Sabundayo BP; Talaat KR; Janiak A; Carmolli MP; Luke CJ; Diehl SA; Durbin AP
    Sci Transl Med; 2016 Mar; 8(330):330ra36. PubMed ID: 27089205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
    Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
    Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
    Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.
    Durbin AP; Pierce KK; Kirkpatrick BD; Grier P; Sabundayo BP; He H; Sausser M; Russell AF; Martin J; Hyatt D; Cook M; Sachs JR; Lee AW; Wang L; Coller BA; Whitehead SS
    Am J Trop Med Hyg; 2020 Aug; 103(2):855-863. PubMed ID: 32394880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
    Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
    Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.
    Lyke KE; Chua JV; Koren M; Friberg H; Gromowski GD; Rapaka RR; Waickman AT; Joshi S; Strauss K; McCracken MK; Gutierrez-Barbosa H; Shrestha B; Culbertson C; Bernal P; De La Barrera RA; Currier JR; Jarman RG; Edelman R
    Lancet Infect Dis; 2024 Aug; 24(8):896-908. PubMed ID: 38679035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
    Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice.
    Brewoo JN; Kinney RM; Powell TD; Arguello JJ; Silengo SJ; Partidos CD; Huang CY; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Feb; 30(8):1513-20. PubMed ID: 22178727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.